Two biotech stocks, Ligand Pharmaceuticals and United Therapeutics, are showing resilient action in Friday’s stock market.
Source: https://www.investors.com/stock-lists/new-highs/biotech-liga…
State Street SPDR S&P Homebuilders ETF remains a Sell due to technical weakness and high downside risk. XHB’s holdings offer sector diversity, but macro headwinds—rising rates, inflation, and market overvaluation—diminish near-term appeal. The probability of further downside is implied based on the fund’s technicals and drawdown history, underscoring risk.
Designed to provide broad exposure to the Large Cap Growth segment of the US equity market, the iShares Top 20 U.S. Stocks ETF (TOPT) is a passively managed exchange traded fund launched on October 23, 2024.
Eli Lilly is at the forefront of the GLP-1 weight loss drug market. The company’s leading position is already being tested by Novo Nordisk’s GLP-1 weight loss pill.
